Opinion: Big Pharma Sold Its Supply Chain in the 1980s. The Bill Is Still Coming Due

A biotech CEO in 2024 negotiates a cell-therapy manufacturing slot with a contract organisation booked eighteen months out. She doesn't own a single piece of the equipment her product will be made on, doesn't employ the operators who will handle it, and doesn't control the schedule that decides whether her patients get treated this year or next. None of that is unusual. It is simply what "having a supply chain" now means for most of the pharmaceutical industry.

That arrangement has a start date. In the early 1980s, large vertically integrated drug makers, the companies that would soon be renamed "Big Pharma," made a strategic bet: sell off manufacturing, distribution and much of development, and keep only two functions in-house, discovering molecules and marketing them. The logic was straightforward. Fixed costs came off the balance sheet, and the risk of expensive failures shifted onto a new layer of contractors built specifically to absorb it.

Leavers and funders join forces

The immediate fallout was a new species of company. Displaced pharma executives, flush with severance and industry contacts, teamed up with investors chasing the returns that marketed drugs were generating, and biotech was born. The model went further still with "virtual pharma," companies of ten or twenty people whose entire operation consists of buying in contractors to do the actual work of drug development, with the exit plan being acquisition by whoever still owns the assets that matter.

Distribution followed the same script. Pharma manufacturers sold off their storage, logistics and last-mile relationships to a wholesaler network now consolidated into three companies, McKesson, Cardinal Health and AmerisourceBergen (now Cencora), severing the direct link between the companies that make medicines and the people who use them.

Generics move in, complexity multiplies

The 1984 Hatch-Waxman Act opened the door for generic manufacturers to take the low-margin, off-patent business Big Pharma was happy to abandon, and generics now supply most of the world's prescription medicines. Layer university spinouts, speciality pharma and biosimilar makers on top, and an industry that once ran on one business model now runs on eight or nine, each with its own contractor base, its own lock-in economics, and its own incentive to optimise its slice rather than the patient outcome at the end of the chain.

The process is the product, and nobody owns the process

The bill for this fragmentation is arriving hardest in biologics and cell and gene therapy, where the manufacturing process is inseparable from the product itself and a single unvalidated temperature excursion can destroy months of work. Autologous therapies add a genuinely circular, vein-to-vein supply chain that this industry's third-party distribution networks were never built to run. Forty years after the first sale, the pharmaceutical supply chain is still discovering, contract by contract, everything it gave away.

Rebuilding it will not happen by reversing course wholesale. It starts with pharma companies deciding which capabilities are too consequential to hand to the lowest-cost bidder, and owning those again.

Hedley Rees is Managing Consultant at PharmaFlow Limited, a UK pharmaceutical supply-chain consultancy he has run since 2005, and former senior supply-chain leader at Bayer UK, British Biotech, Vernalis, J&J, and OSI Pharmaceuticals (now Astellas). The views expressed in this article do not necessarily reflect those of The Supply Chainer or its editorial team.